Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial.

ABSTRACT:

Importance

Dual thrombolytic treatment with small bolus alteplase and mutant prourokinase has the potential to be a safer and more efficacious treatment for ischemic stroke than alteplase alone because mutant prourokinase is designed to act only on degraded fibrin without affecting circulating fibrinogen.

Objective

To assess the safety and efficacy of this dual thrombolytic treatment compared with alteplase.

Design, setting, and participants

This controlled, open-label randomized clinical trial with a blinded end point was conducted from August 10, 2019, to March 26, 2022, with a total follow-up of 30 days. Adult patients with ischemic stroke from 4 stroke centers in the Netherlands were enrolled.

Interventions

Patients were randomized (1:1) to receive a bolus

SUBMITTER: van der Ende NAM 

PROVIDER: S-EPMC10203964 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature